Venture-stage investment
Platypus Bio
A biotechnology company developing programmable RNA-sensing platforms for next-generation therapeutics and diagnostics.
Therapeutics RNA-sensing · Therapeutics and diagnostics
Chris Alma as a judge at Challenger Pitch for Health 2026.
The science · The story
A venture-stage stake in an established Australian programme.
Many diseases are defined by unique RNA signals inside cells. Platypus Bio is building technologies that detect these signals and translate them into precise biological responses.
By linking RNA recognition directly to functional biological outcomes, its platforms aim to enable the programmable elimination of diseased cells and rapid detection of disease-associated RNA signatures — unlocking new classes of precision medicines and molecular diagnostics.
Proto Axiom was a first investor.
- Invested
- 2026
- Origin
- Sydney, Australia
- Sector
- Therapeutics
- Modality
- RNA-sensing · Therapeutics and diagnostics
Leadership
Independently led; see the company website for the full team.
Chris Alma
Founder & Chief Executive Officer
Platypus Bio
Programme status
Where the programme is now, and what comes next.
- Now
- Building technologies to transform RNA sensing into actionable biological outcomes across a wide range of medical applications.
In the press
Recent news.
[ Press mentions to be added as they publish. ]